Voya Investment Management LLC Has $3.59 Million Holdings in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Voya Investment Management LLC increased its stake in Prestige Consumer Healthcare by 19.5% in the first quarter, owning approximately $3.59 million worth of shares.
• Prestige Consumer Healthcare reported a decrease in quarterly revenue of 6.6% year-over-year, with an EPS of $0.95, falling short of analysts' expectations.
• The company's stock has seen recent downgrades in analyst ratings, with Zacks Research lowering its rating from "hold" to "strong sell," as three analysts rate it as buy and three as hold.

Voya Investment Management LLC raised its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 19.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,717 shares of the company's stock after buying an additional 6,798 shares during the period. Voya Investment Management LLC owned about 0.08% of Prestige Consumer Healthcare worth $3,586,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of PBH. Cetera Investment Advisers acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $413,000. Focus Partners Wealth bought a new position in Prestige Consumer Healthcare during the fourth quarter worth $235,000. Quantinno Capital Management LP lifted its stake in shares of Prestige Consumer Healthcare by 8.9% during the 4th quarter. Quantinno Capital Management LP now owns 9,013 shares of the company's stock worth $704,000 after buying an additional 739 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of Prestige Consumer Healthcare by 44.4% during the 4th quarter. ProShare Advisors LLC now owns 14,925 shares of the company's stock worth $1,165,000 after buying an additional 4,590 shares during the last quarter. Finally, Vident Advisory LLC lifted its stake in shares of Prestige Consumer Healthcare by 2.8% during the 4th quarter. Vident Advisory LLC now owns 11,254 shares of the company's stock worth $879,000 after buying an additional 305 shares during the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH traded down $0.28 during trading hours on Tuesday, hitting $63.32. 15,757 shares of the stock were exchanged, compared to its average volume of 416,148. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The company has a market cap of $3.12 billion, a PE ratio of 14.86, a price-to-earnings-growth ratio of 1.99 and a beta of 0.46. The company's fifty day simple moving average is $68.81 and its two-hundred day simple moving average is $78.20. Prestige Consumer Healthcare Inc. has a 1-year low of $61.93 and a 1-year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. During the same quarter in the prior year, the business posted $0.90 EPS. The business's revenue was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on PBH shares. Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Zacks Research downgraded Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a report on Thursday, September 4th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of "Hold" and an average target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.